New Launch19 Dec 2025, 09:54 am
Zydus Lifesciences to Launch Cancer-Risk Assessment Diagnostic Tests in India in Collaboration with Myriad Genetics
AI Summary
Zydus Lifesciences Limited has signed an agreement with Myriad Genetics to introduce cancer-risk assessment diagnostic tests in India. The agreement includes the marketing and distribution of MyRisk® Hereditary Cancer Test, MyChoice® HRD Plus Test for ovarian cancer, and Prolaris® a gene expression Prostate Cancer Prognostic Test. These tests are widely adopted in North America, Europe, and major global cancer centers and will now be available in India to empower Indian oncologists with cutting-edge genomic decision-support tools.
Key Highlights
- Zydus Lifesciences Limited has signed an agreement with Myriad Genetics to launch cancer-risk assessment diagnostic tests in India.
- The agreement includes the marketing and distribution of MyRisk® Hereditary Cancer Test, MyChoice® HRD Plus Test for ovarian cancer, and Prolaris® a gene expression Prostate Cancer Prognostic Test.
- These tests are widely adopted in North America, Europe, and major global cancer centers and will now be available in India.
- The tests are designed to help people safeguard their health, understand disease progression, and inform the right treatment path.
- The collaboration aims to strengthen clinician education and diagnostic infrastructure in India.